Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Synovial joint-on-a-chip for modeling arthritis: progress, pitfalls, and potential

Li ZA., Sant S., Cho SK., Goodman SB., Bunnell BA., Tuan RS.

Narrative Review on Osteoarthritis, Autoimmune Research, published in Trends Biotechnol (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Trends Biotechnol (2023)
Reported sample size
—
Source database
Europe PMC
PMID
35995600
PMCID
PMC9938846
DOI
10.1016/j.tibtech.2022.07.011
Citations
60

Abstract (original English)

Disorders of the synovial joint, such as osteoarthritis (OA) and rheumatoid arthritis (RA), afflict a substantial proportion of the global population. However, current clinical management has not been focused on fully restoring the native function of joints. Organ-on-chip (OoC), also called a microphysiological system, which typically accommodates multiple human cell-derived tissues/organs under physiological culture conditions, is an emerging platform that potentially overcomes the limitations of current models in developing therapeutics. Herein, we review major steps in the generation of OoCs for studying arthritis, discuss the challenges faced when these novel platforms enter the next phase of development and application, and present the potential for OoC technology to investigate the pathogenesis of joint diseases and the development of efficacious therapies.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansArthritis, RheumatoidOsteoarthritisMicrophysiological Systems

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research